The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | Gastric cancer: advancing care through precision strategies
In this latest episode of the VJOncoAlert Journal Club, Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a landmark Lancet review exploring recent progress in gastroesophageal adenocarcinoma. Key breakthroughs include HER2-targeted therapy, immunotherapy in biomarker-selected and unselected populations, and the emergence of claudin inhibitors.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
